## 5. Research Compute Strategy

The preceding chapter established that OpenDiabetic's developer platform includes a model evaluation harness and compute credits for builders, with the data ownership doctrine requiring research opt-in and de-identification standards. This chapter translates those principles into operational infrastructure: the federated learning coordination, synthetic data pipelines, trusted research environments, and public accounting mechanisms that enable privacy-preserving diabetes research at scale. The central question is not whether privacy-preserving research compute is technically feasible — federated learning for diabetes prediction has achieved 91–97.27% accuracy in peer-reviewed studies [^3^], and synthetic CGM data has been generated at the scale of 40{,}000 synthetic days [^339^] — but whether a nonprofit foundation can operate this infrastructure as a public good without replicating the data-harvesting patterns of commercial platforms. Three structural mechanisms make this possible: open research credits with participatory allocation, a defense-in-depth privacy infrastructure combining FL with synthetic data and trusted research environments, and a strict clinical boundaries framework that separates compute provision from patient care.

---

### 5.1 Open Research Credits and Nonprofit Compute Grants

#### 5.1.1 Compute Credit Model

Qualifying researchers receive free access to three categories of infrastructure: **federated learning coordination nodes** for cross-institutional model training without data centralization; **synthetic data generation pipelines** for creating statistically faithful diabetes datasets shareable without privacy constraints; and **model evaluation harnesses** for testing diabetic education LLMs against standardized benchmarks. This model targets the simulation-to-reality gap in FL research: only 10 of 107 reviewed FL healthcare studies reported real-world distributed clinical deployments, with the majority (78 of 107) using custom-designed rather than open-source frameworks [^64^]. By providing production-grade infrastructure at no cost, OpenDiabetic removes the economic barrier that forces most researchers to simulate distribution by artificially partitioning centrally held data.

The credit system operates in three tiers. Tier 1 (micro-credits up to $500/quarter) supports individual researchers with synthetic data generation, evaluation harness access, and participation in existing federated training rounds. Tier 2 (up to $5{,}000/quarter) funds principal investigators leading multi-site studies with dedicated FL node hosting and custom model support. Tier 3 (unlimited, with engineering support) serves consortium-scale projects involving five or more clinical sites, with full-stack FL operations including secure aggregation, differential privacy accounting, and regulatory documentation. This tiered approach adapts the Apache Software Foundation's model of supporting 350+ projects with lean infrastructure spending [^452^] to the higher compute demands of healthcare AI.

#### 5.1.2 Grant Programs

OpenDiabetic directly funds research through privacy-preserving diabetes research grants, supported by foundation operating budgets and philanthropic partners. Two conditions bind every grant: funded research must use privacy-enhancing technologies (federated learning, differential privacy, synthetic data, or trusted research environments) as the primary data handling methodology, and researchers must commit to open-access publication. The latter condition ensures that public funding produces public knowledge, not proprietary intellectual property locked behind publisher paywalls.

Grant sizes range from $25{,}000 exploratory awards for methodological development to $250{,}000 multi-year project grants for clinical validation. Priority areas include: real-world FL deployment in diabetes care (addressing the 91% simulation rate [^64^]); synthetic data generation for underrepresented populations; bias evaluation in diabetic AI (responding to the finding that only 3.6% of FDA-authorized AI/ML devices reported race/ethnicity of validation cohorts [^176^]); and edge AI deployment for low-resource settings.

#### 5.1.3 Research Credit Allocation: Transparent Criteria and Participatory Review

Allocation decisions are governed by a participatory review committee including academic researchers, privacy experts, clinicians, and people with diabetes. Community member inclusion follows established biobank governance precedent: research on health data trusts finds that legitimacy "relies on open and accountable engagement with stakeholders" with "careful consideration given to who is involved, why they are involved, at what stage and for what purpose" [^432^]. The Charlotte Regional Data Trust applies three questions to every data use request: Is it legal? Is it ethical? Is it a good idea? [^430^] OpenDiabetic uses the same tripartite test for every credit application.

Allocation criteria are public and weighted across three dimensions. **Public benefit** (40% weight): does the research address a clinically meaningful question? Does it serve underrepresented populations? **Methodological rigor** (35% weight): is the study design sound? Are privacy guarantees technically defensible? **Open data commitment** (25% weight): will outputs be published open-access? Will code and synthetic datasets be released under permissive licenses? Will negative results be reported? This last criterion counteracts the publication bias that distorts evidence bases by suppressing null or unfavorable findings.

---

### 5.2 Privacy-Preserving Research Infrastructure

#### 5.2.1 Federated Learning Coordination: Cross-Institutional Research Without Data Centralization

The core technical infrastructure is an FL coordination service purpose-built for diabetes research. The service enables multiple institutions — academic medical centers, community clinics, device manufacturers with patient consent — to collaboratively train models without patient data leaving its origin location. OpenDiabetic builds on established open-source frameworks rather than reinventing them, providing diabetes-specific orchestration, data model adapters, and operational support that makes these tools usable for clinical researchers who are not distributed systems engineers.

| Platform | Open-Source | Diabetes-Specific | Key Strength | Key Limitation | OpenDiabetic Integration Role |
|---|---|---|---|---|---|
| PySyft | Yes (9{,}200+ stars) [^146^] | No | DP + SMPC + HE combined; mathematical privacy guarantees | Higher computational overhead; steep learning curve | Privacy layer for sensitive cohort studies requiring mathematical guarantees |
| Flower | Yes (6{,}600+ stars) [^140^] | No | Framework-agnostic (PyTorch, TF, JAX); used by NHS and Owkin | Requires custom data model adapters | Primary orchestration layer; diabetes FHIR adapters provided by OpenDiabetic |
| NVIDIA FLARE | Yes (523 stars) [^146^] | Partial (healthcare-optimized) | Edge deployment; low-latency inference | Smaller community; NVIDIA ecosystem tie-in | Edge deployment for hospital-based FL nodes and low-resource settings |
| FATE | Yes (5{,}500 stars) [^146^] | No | Enterprise-grade; Kubernetes; mature security | Heavy infrastructure requirements; complex deployment | Large-scale consortium deployments with dedicated DevOps support |
| OpenMined | Yes (nonprofit) [^121^] | No | Nonprofit mission alignment; privacy education | Smaller engineering team; slower development | Strategic partner for privacy education and PySyft advancement |

No single framework satisfies all diabetes research requirements. PySyft provides the strongest privacy guarantees but at computational cost; Flower offers the most flexible deployment but lacks diabetes-specific data models; NVIDIA FLARE optimizes for edge but ties to a vendor ecosystem. OpenDiabetic's role mirrors 2i2c's approach to research education infrastructure [^478^]: providing the integration layer that makes these frameworks collectively usable, rather than competing with any of them.

The coordination service includes reference implementations for the two diabetes-specific FL approaches with the strongest clinical validation. **Clu-FDL** groups patients by carbohydrate intake patterns for personalized glucose prediction, achieving precision 0.93, recall 0.96, and RMSE 11.08 ± 1.77 mg/dL [^1^]. **FedGlu** improves glycemic excursion detection by 35% over local-only models through a novel loss function that penalizes errors more heavily in clinically dangerous glucose ranges [^145^]. OpenDiabetic distributes these as pre-configured Docker containers with Flower orchestration, enabling replication and extension.

The service also addresses the non-IID challenge that is the norm in diabetes data. Patient populations differ across geography, socioeconomic status, device type, and disease subtype. Standard FedAvg suffers accuracy drops of 5.9–17.6% under non-IID distributions [^160^]. The coordination service automatically applies FedProx for convergence stability and implements clustering-based personalization following the Clu-FDL pattern, so researchers do not need to become FL algorithm specialists to run robust multi-site studies.

#### 5.2.2 Synthetic Data Generation Pipeline: CTGAN, GluGAN, and UVA/Padova Integration

Synthetic data generation complements federated learning by creating shareable datasets that preserve statistical properties of real patient data without containing actual patient records. OpenDiabetic operates a three-component pipeline.

**Tabular health data generation** uses CTGAN and CopulaGAN from MIT's Synthetic Data Vault with a divide-and-conquer strategy achieving AUC scores of 0.733–0.786 on diabetes classification tasks, outperforming standard CTGAN by up to 20 percentage points [^345^]. A 2026 study synthesized longitudinal datasets from nearly 1 million individuals with diabetes, finding that models trained on synthetic data tracked real-data performance with only a slight gap — but also identifying a critical threshold where diagnoses below 0.05% prevalence exhibited substantially increased relative error [^331^]. This finding establishes the boundary: synthetic data excels for common diabetes phenotypes but requires real-data augmentation for rare complications.

**CGM time-series generation** uses GluGAN, which across three clinical datasets with 47 type 1 diabetes subjects outperformed four baseline GAN models on all clinical metrics and significantly reduced glucose predictor RMSE over 30- and 60-minute horizons when used for training augmentation [^342^]. A conditional GAN approach has generated 40{,}000 synthetic CGM days (940{,}000 hours) conditioned on HbA1c levels [^339^], made publicly available for algorithm development.

**In-silico trial integration** connects to the UVA/Padova Type 1 Diabetes Mellitus Simulator, FDA-approved as a substitute for preclinical trials for closed-loop insulin delivery algorithms [^353^]. The simulator includes cohorts of 100 in-silico adults, 100 adolescents, and 100 children with subject-specific parameters, enabling virtual clinical trials without human subject risk.

Quality validation is mandatory and transparent. Every synthetic dataset is evaluated across fidelity (statistical similarity), utility (downstream ML effectiveness), and privacy (re-identification risk) [^334^], with results published alongside release. This addresses the documented risk that even widely-used generators contain severe inaccuracies — Synthea overestimated diabetes-related amputations by 4{,}000× in its initial version [^330^].

#### 5.2.3 Trusted Research Environment (TRE) Model: Remote Access with Full Audit Trails

For research requiring real patient data, OpenDiabetic operates a Trusted Research Environment: researchers bring code to the data, not data to their code. Full audit trails capture every query, analysis, and screen view. No data export is permitted; only computational guarantees (aggregated statistics, model parameters, evaluation metrics) leave the environment.

This approach follows proven precedent. A UK Government pilot combining TREs with federated querying and differential privacy (epsilon = 1) enabled NHS England and the US National Cancer Institute to study ultra-rare childhood tumors, reducing information governance timelines from over a year to approximately two months [^433^]. The pilot demonstrated that layered privacy-enhancing technologies — federated querying executing inside institutional firewalls, trusted execution environments decrypting aggregates in secure enclaves, and differential privacy with cell suppression for small counts — can together satisfy both strict privacy requirements and legitimate research needs [^433^]. OpenDiabetic adapts this proven multi-layer approach for diabetes research. TRE access requires committee approval, operates on time-limited contracts (6–12 months), and archives all executed code for reproducibility auditing.

---

### 5.3 Model Evaluation and Education

#### 5.3.1 Diabetic Education Model Testing: Standardized Benchmarks

Chapter 4 introduced the Model Evaluation Harness for agent-bound LLMs. In the research context, the harness serves as a public benchmark: any researcher can submit models for evaluation, creating competitive pressure for improvement and transparent accountability for safety failures. The harness tests four dimensions: **accuracy** (95%+ required on ADA Standards of Care-derived questions); **safety** (1{,}000+ adversarial prompts designed to elicit dangerous responses, with zero tolerance for unsafe output); **cultural sensitivity** (consistent response quality across implied demographic characteristics); and **reading-level appropriateness** (adjustment to patient-indicated health literacy). The latter two dimensions directly address the finding that only 3.6% of FDA-authorized AI/ML devices reported race/ethnicity of validation cohorts [^176^], indicating systematic demographic fairness neglect in medical AI evaluation. Results are published openly as per-model scorecards.

#### 5.3.2 Public-Good Compute Ledger: Transparent Accounting

Every compute resource allocated to research — GPU hours, FL node runtime, synthetic data generation cycles, TRE access time — is recorded in a public-good compute ledger published quarterly. The ledger reports: aggregate compute hours by research category; participating institution and country counts; outcomes metrics (publications, open-source releases, clinical deployments); and impact indicators (patient populations studied, underrepresented groups included, real-world deployment status). This transparent accounting demonstrates return on investment for donors, shows the diabetic community how resources are allocated, and provides the broader field with empirical cost data for privacy-preserving diabetes research. It also addresses the "adjacent funding" problem — the vast majority of open infrastructure funding is indirect, bundled into research grants rather than designated for infrastructure [^403^] — by making infrastructure costs visible as a separate line item, following the precedent of Invest in Open Infrastructure's work on open scholarly infrastructure [^470^].

---

### 5.4 Clinical Partner Boundaries

#### 5.4.1 Clear Separation: Compute Infrastructure, Not Clinical Services

OpenDiabetic provides compute infrastructure for research. It does not provide clinical services. This boundary is absolute, legally enforced, and communicated unambiguously. No OpenDiabetic system, employee, or representative may deliver diagnostic assessments, treatment recommendations, dosage advice, or emergency medical guidance. No OpenDiabetic-funded research may claim clinical efficacy without independent validation by academic medical centers with appropriate IRB approvals.

The separation serves three purposes. **Regulatory clarity**: the FDA has not issued FL-specific guidance, but its Good Machine Learning Practice principles — covering multi-disciplinary expertise, representative datasets, independent test sets, clinical testing, transparency, and post-deployment monitoring [^175^] — apply directly to FL-based research. By disclaiming clinical services, OpenDiabetic operates in the research infrastructure space where frameworks are clearer. **Liability protection**: clinical decision-making carries malpractice liability; infrastructure provision does not. **Trust preservation**: the structural trust moat from Chapter 3 depends on OpenDiabetic never being perceived as a healthcare provider that might prioritize research over patient welfare.

The separation is operationalized through technical and contractual mechanisms. All SDK agents enforce non-diagnostic constraints at the infrastructure level (Section 4.4.3). All research partnerships require explicit agreements specifying that OpenDiabetic provides compute resources only, with clinical validation, patient recruitment, and results interpretation the sole responsibility of the academic partner. All publications from OpenDiabetic-funded research must include a disclaimer stating that the compute infrastructure provider had no role in clinical decision-making, patient care, or results interpretation.

#### 5.4.2 Partnership Model: Independent Academic Validation

Clinical validation of any research output is conducted exclusively by independent academic medical centers. Partnership agreements specify that OpenDiabetic provides compute infrastructure and technical support; the academic partner provides data (under its own IRB approvals), clinical expertise, and validation methodology. Co-development agreements assign intellectual property to the partnership with licensing under permissive open-source terms.

This model follows the EXAM study, one of the largest successful clinical FL deployments: 20 institutions across four continents achieved AUC > 0.92 for predicting COVID-19 oxygen requirements, with 16% average improvement over local models, completed in two weeks with no data shared or leaving hospital locations [^119^]. NVIDIA provided the FL platform; clinical validation was conducted entirely by participating medical centers. OpenDiabetic follows the same division of labor.

Research partnerships proceed in three phases. **Phase 1 (feasibility)**: 3–6 months of synthetic data prototyping and model exploration using compute credits — no patient data. **Phase 2 (validation)**: 12–24 months of IRB-approved clinical validation at partner sites, with OpenDiabetic providing FL coordination and TRE access. **Phase 3 (dissemination)**: open publication, open-source release, and community maintenance. OpenDiabetic's involvement decreases across phases: heavy in Phase 1 (infrastructure setup), moderate in Phase 2 (operational support), minimal in Phase 3 (community stewardship). This graduated approach prevents OpenDiabetic from becoming a permanent dependency for projects that should eventually sustain themselves through community contribution and follow-on funding.
